Abraham Fisher

Summary

Country: Israel

Publications

  1. ncbi AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona
    J Mol Neurosci 19:145-53. 2002
  2. ncbi M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy
    Abraham Fisher
    Israel Institute for Biological Research, 74100 Ness Ziona, Israel
    J Mol Neurosci 20:349-56. 2003
  3. ncbi M1 receptors play a central role in modulating AD-like pathology in transgenic mice
    Antonella Caccamo
    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA
    Neuron 49:671-82. 2006
  4. ncbi Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, PO Box 19, Ness Ziona, Israel
    Neurotherapeutics 5:433-42. 2008
  5. ncbi Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona, Israel
    J Neurochem 120:22-33. 2012
  6. ncbi M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona, Israel
    Neurodegener Dis 5:237-40. 2008
  7. ncbi M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update
    Abraham Fisher
    Israel Institute for Biological Research, P O Box 19, 74100 Ness Ziona, Israel
    Curr Alzheimer Res 4:577-80. 2007
  8. ncbi Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
    A Fisher
    Israel Institute for Biological Research, Ness Ziona
    Jpn J Pharmacol 84:101-12. 2000
  9. ncbi M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives
    A Fisher
    Israel Institute for Biological Research, P O Box 19, Ness Ziona 74100, Israel
    Ann N Y Acad Sci 920:315-20. 2000
  10. ncbi Hip flexion and lumbar puncture: a radiological study
    A Fisher
    Division of Anesthesiology and Intensive Care, Soroka University Medical Center and Ben Gurion University of the Negev, Beersheva 84101, Israel
    Anaesthesia 56:262-6. 2001

Collaborators

Detail Information

Publications14

  1. ncbi AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona
    J Mol Neurosci 19:145-53. 2002
    ..Our M1 agonists, alone or in polypharmacy, may present a unique therapy in AD due to their beneficial effects on major hallmarks of AD...
  2. ncbi M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy
    Abraham Fisher
    Israel Institute for Biological Research, 74100 Ness Ziona, Israel
    J Mol Neurosci 20:349-56. 2003
    ..This may place such drugs in the first line of modern AD therapies (e.g., beta- or gamma-secretase inhibitors, vaccines against Abeta, statins, and inhibitors of tau hyperphosphorylation)...
  3. ncbi M1 receptors play a central role in modulating AD-like pathology in transgenic mice
    Antonella Caccamo
    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA
    Neuron 49:671-82. 2006
    ..Therefore, selective M1 agonists may be efficacious for the treatment of AD...
  4. ncbi Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, PO Box 19, Ness Ziona, Israel
    Neurotherapeutics 5:433-42. 2008
    ..Among the reviewed treatments, M1 selective agonists emerge, in particular, as potential disease modifiers...
  5. ncbi Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona, Israel
    J Neurochem 120:22-33. 2012
    ..This major requirement may be fulfilled with M1-selective muscarinic agonists and less with other reviewed cholinergic treatments...
  6. ncbi M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors
    Abraham Fisher
    Israel Institute for Biological Research, Ness Ziona, Israel
    Neurodegener Dis 5:237-40. 2008
    ..AF267B is the first reported low-molecular-weight therapy that targets the major AD hallmarks...
  7. ncbi M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update
    Abraham Fisher
    Israel Institute for Biological Research, P O Box 19, 74100 Ness Ziona, Israel
    Curr Alzheimer Res 4:577-80. 2007
    ..In this context, AF267B is the 1(st) reported low MW CNS-penetrable mono-therapy that meets this challenge. Clinical trials will determine if AF267B may become an important therapy in AD...
  8. ncbi Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
    A Fisher
    Israel Institute for Biological Research, Ness Ziona
    Jpn J Pharmacol 84:101-12. 2000
    ..This property of M1 agonists to alter different aspects associated with AD pathogenesis could represent the most remarkable clinical value of such drugs...
  9. ncbi M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives
    A Fisher
    Israel Institute for Biological Research, P O Box 19, Ness Ziona 74100, Israel
    Ann N Y Acad Sci 920:315-20. 2000
    ..This unique property of M1 agonists to alter different aspects of AD pathogenesis could represent the most remarkable, yet unexplored, clinical value of such compounds...
  10. ncbi Hip flexion and lumbar puncture: a radiological study
    A Fisher
    Division of Anesthesiology and Intensive Care, Soroka University Medical Center and Ben Gurion University of the Negev, Beersheva 84101, Israel
    Anaesthesia 56:262-6. 2001
    ..Hip flexion in the sitting position will anatomically optimise lumbar interspinous space width for needle passage, and statistically significant increases in space width have been demonstrated increasing progressively from L2-3 to L4-5...
  11. ncbi Reduction in distractibility with AF102B and THA in the macaque
    JOSEPH O'NEILL
    University of California Los Angeles Neuropsychiatric Institute 47 417A, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
    Pharmacol Biochem Behav 76:301-6. 2003
    ..Reaction time at best dose decreased for both drugs, but not significantly. Muscarinic agonists and cholinesterase inhibitors may reduce distractibility in primates...
  12. ncbi M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway
    Ginny G Farías
    Centro FONDAP de Regulación Celular y Patología Joaquín V Luco, MIFAB, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile
    Neurobiol Dis 17:337-48. 2004
    ..We conclude that the cross-talk between the muscarinic signaling and Wnt components underlie the neuroprotective effect of the M1 mAChR activation...
  13. ncbi M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity
    Moustapha Alfa Cissé
    Institut de Pharmacologie Moleculaire et Cellulaire, 06560 Valbonne, France
    J Neurosci 27:4083-92. 2007
    ..Thus, our data provide strong evidence that muscarinic receptor activation increases the physiological processing of PrP(c) by upregulating the phosphorylation state and activity of ADAM17 protease...
  14. ncbi The 8th International Conference on Alzheimer's and Parkinson's Diseases. Preface
    Israel Hanin
    Neurodegener Dis 5:113. 2008